Table of Contents Author Guidelines Submit a Manuscript
Volume 2017 (2017), Article ID 3106890, 7 pages
Research Article

Efficacy and Tolerability of Intravenous Ferric Carboxymaltose in Patients with Iron Deficiency at a Hospital Outpatient Clinic: A Retrospective Cohort Study of Real-World Clinical Practice

1Hospital de Dia de Imuno-Hemoterapia, Hospital Pulido Valente, Centro Hospitalar Lisboa Norte (CHLN), Alameda das Linhas de Torres 117, 1769-001 Lisboa, Portugal
2Hospital de Dia de Imuno-Hemoterapia, Hospital de Santa Maria, CHLN, Avenida Prof. Egas Moniz, 1649-035 Lisboa, Portugal

Correspondence should be addressed to António Robalo Nunes

Received 17 March 2017; Revised 29 May 2017; Accepted 1 June 2017; Published 3 July 2017

Academic Editor: Ajit C. Gorakshakar

Copyright © 2017 António Robalo Nunes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Ferric carboxymaltose (FCM) is an intravenous iron formulation to correct iron deficiency. Although its use has been extensively studied in clinical trials, real-world evidence regarding FCM treatment is scarce. Our aim was to evaluate the efficacy and tolerability of FCM treatment in patients with iron deficiency, with or without anemia, at a hospital outpatient clinic. Data was collected retrospectively from medical records. During this 2-year study, 459 patients were included. Mean age was 58.6 ± 17.5 years and most patients received cumulative FCM doses of 501–1000 mg (63.2%). Six weeks after administration of FCM, efficacy endpoints hemoglobin increase ≥2 g/dL, hemoglobin increase ≥3 g/dL, and transferrin saturation > 20% were attained by 41%, 20%, and 63% of patients, respectively. Patients who received higher FCM doses showed significant reduced odds of not achieving hemoglobin increase ≥2 g/dL (501–1000 mg, adjusted odds ratio [OR]: 0.34, 95% confidence interval [CI] 0.18–0.62; 1001–3000 mg, OR: 0.19, 95% CI 0.07–0.49), compared to 500 mg doses. Treatment-emergent adverse events were documented in <4% of patients. In conclusion, FCM treatment was effective and well-tolerated by outpatients with iron deficiency at a hospital clinic, and its dosage should be adjusted to improve iron deficiency management in clinical practice.